Pressmeddelanden

Stockholm, Sverige – 2025-04-24 - Inhalation Sciences AB (ISAB) har slutfört den FDA-finansierade studien[1] av DissolvIt® (ISAB:s egenutvecklade unika metodologi för upplösningstestning av inhalerade läkemedel) med framgångsrika resultat där samtliga primära och sekundära studiemål bekräftats uppnådda. Efter slutgiltiga mindre kompletteringar har studierapporten nu godkänts av FDA för publicering.

Stockholm, Sweden - April 24, 2025 - Inhalation Sciences AB (ISAB) has completed the FDA-funded study[1] of DissolvIt® (ISAB's proprietary unique methodology for dissolution testing of inhaled drugs) with successful results where all primary and secondary study objectives were confirmed to be met. After final minor amendments, the study report has now been approved by the FDA for publication.

Stockholm, Sverige - 2025-04-15 – Inhalation Sciences AB (ISAB) har erhållit en inköpsorder från en återkommande global kund. Ordern, som värderas till 41.000 euro, omfattar ytterligare instrument och kompletterande utrustning för avancerad inhalationsforskning.

Stockholm, Sweden – April 15, 2025 – Inhalation Sciences AB (ISAB) has received a purchase order from a recurring global customer. The order, valued at 41,000 EUR, includes additional instruments and complementary equipment for advanced inhalation research.

Aktieägarna i Inhalation Sciences Sweden AB (publ), org.nr 556665-6038, (”Bolaget”) kallas härmed till extra bolagsstämma torsdagen den 8 maj 2025 kl.13.00 i Bolagets lokaler på Hälsovägen 7 i Huddinge. Rösträttsregistrering startar kl.12.30.

Styrelsen i Inhalation Sciences Sweden AB (publ) ("ISAB" eller "Bolaget") har idag fattat beslut om att föreslå att en extra bolagsstämma beslutar om att genomföra en nyemission av units (”Units”) med företrädesrätt för befintliga aktieägare om cirka 15,2 MSEK (”Företrädesemissionen”). Företrädesemissionen är säkerställd till cirka 80 procent genom teckningsförbindelser och garantiåtaganden, motsvarande cirka 12 MSEK. Genom emissionslikviden kommer Bolaget ha möjlighet att kapitalisera på den offertstock som uppgick till 45 MSEK per sista mars 2025 (20 MSEK per sista mars 2024) och genomföra framåtriktade tillväxtssatsningar. Bolagets styrelse har även fattat beslut om att efter genomförd företrädesemission utreda strategiska alternativ för Bolaget vilket även inkluderar möjligheten till en försäljning av Bolaget eller dess verksamhet.

Stockholm, Sweden – March 3, 2025 – Inhalation Sciences AB (ISAB), a leader in inhalation research and drug development, welcomes the U.S. Food and Drug Administration’s (FDA) latest guidelines[1], which establish dissolution testing as a key method for evaluating inhaled drug products. The updated recommendations reinforce the relevance of ISAB’s proprietary DissolvIt® system, which has already been the focus of an FDA-financed study aimed at improving regulatory science in inhalation drug development.

(Stockholm, Sverige, 28 februari 2025) Inhalation Sciences AB meddelar att bolagets delårsrapport för det fjärde kvartalet 2024 nu finns tillgänglig på bolagets hemsida. För att läsa hela rapporten vänligen besök: http://inhalation.se/investors/finansiella-rapporter/

(Stockholm, Sweden, 28 February 2025) Inhalation Sciences AB announces that its Q4 / Year-End Report for 2024 is now available on the company’s website. To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiellarapporter/

(Stockholm, Sweden, 13 January 2025) Inhalation Sciences (ISAB) announces its plans to launch the company’s XposeALI[®] in vitro exposure module, now with microperfusion. The development work was undertaken in 2024 with the final testing and validation being performed in a study co-financed with one of the company’s longstanding global pharmaceutical customers.

(Stockholm, Sweden, 10 January 2025) Inhalation Sciences AB (ISAB) has received an order worth SEK 212,000 from a returning client, a global leader in generics and biosimilars, for an Inhalation Research Services (IRS) project.

(Stockholm, Sweden, 9 January 2025) Inhalation Sciences Sweden AB (ISAB) is proud to announce the submission of the project report and summary data to the U.S. Food and Drug Administration (FDA) for final review and approval. This marks a key milestone in ISAB’s ongoing FDA BAA (Broad Agency Agreement) Contract 75F40122C00197 for a collaborative research project which evaluates the discriminative dissolution potential of its innovative DissolvIt[®] system for assessing drug formulations designed for inhalation therapy.

(Stockholm, Sweden, 17 December 2024) Inhalation Sciences AB (publ), a world-leading research and development company in the field of inhalation, is pleased to announce the receipt of new orders for technical service contracts, totalling 33,900 Euro, from two recurrent customers in Europe.

(Stockholm, Sverige, 20 november 2024) Inhalation Sciences AB meddelar att bolagets delårsrapport för det tredje kvartalet 2024 nu finns tillgänglig på bolagets hemsida.

(Stockholm, Sweden, 20 November, 2024) Inhalation Sciences AB announces that its Q3 Report for 2024 is now available on the company's website.

(Stockholm, 16 October 2024) Inhalation Sciences Sweden AB (ISAB) today releases the latest update on progress in its FDA BAA (Broad Agency Agreement) dissolution collaborative research project evaluating the discriminative power of ISAB’s DissolvIt[®] in comparing drug formulations aimed for administration via inhalation. The project - contract number 75F40122C00197 - was communicated by ISAB on September 15[th], 2022, with updates throughout 2023.

A new publication demonstrates how XposeALI[®], Inhalation Sciences’ in vitro cell-based exposure module, successfully predicted the toxicity of inhaled palladium nanoparticles, an emerging pollutant from motor vehicles, in the lung lining. The study was carried out, and the paper co-authored, by scientists from Karolinska Institutet and the Swedish University of Agricultural Sciences as well as Inhalation Sciences. The paper is published in Frontiers in Medicine (Pulmonary Medicine section).

Inhalation Sciences Sweden AB (publ) (”Bolaget”) avhöll den 4 september 2024 extra bolagsstämma. Vid stämman fattades följande beslut.

(Stockholm, Sverige, 28 augusti 2024) Inhalation Sciences AB meddelar att bolagets delårsrapport för andra kvartalet 2024 finns nu tillgänglig på bolagets hemsida.

(Stockholm, Sweden, 28 August 2024) Inhalation Sciences AB announces that its Q2 Report for 2024 is now available on the company’s website.

Aktieägarna i Inhalation Sciences Sweden AB (publ), org.nr 556665-6038, (”Bolaget”) kallas härmed till extra bolagsstämma den 4 september 2024 kl. 13.00 i Bolagets lokaler på Hälsovägen 7 i Huddinge. Rösträttsregistrering startar kl. 12.30.

(Stockholm, 15 August 2024) Inhalation Sciences AB (ISAB) has received a surge of new orders, primarily for its Inhalation Research Services, as the summer season comes to a close and the company and wider inhalation industry gear up for a busy second half of the year.

Inhalation Sciences Sweden AB’s (publ) (“Inhalation Sciences” or the “Company”) Nomination Committee proposes that Ulf Ericsson be elected as new Board member.

(Stockholm, 13 June 2024) Inhalation Sciences AB (ISAB) has received its first order for a preclinical dissolution study using its high-precision DissolvIt® technology from a returning customer who is one of the world’s top 10 big pharma companies developing inhaled pharmaceuticals. The order is worth 57,000 EURO - over 600,000 SEK.

Inhalation Sciences CEO Manoush Masarrat discusses the company’s recent Q1 Report, and takes investors’ questions, in the first of a new regular series.

(Stockholm, Sverige, 28 maj 2024) Inhalation Sciences AB meddelar att bolagets delårsrapport för första kvartalet 2024 finns nu tillgänglig på bolagets hemsida.

(Stockholm, Sweden, 28 May 2024) Inhalation Sciences AB announces that its Q1 Report for 2024 is now available on the company’s website.

On 20 May Inhalation Sciences AB CSO Per Gerde presented the company’s predictive tools for developing and assessing generic inhaled pharmaceuticals at the FDA’s public GDUFA (Generic Drug User Fee Amendments) webinar (as previously communicated on April 10, 2024). The webinar was well-attended and well-received by a large audience of specialist industry professionals.

Inhalation Sciences AB (ISAB) has received a purchase order worth 60,000 EURO (almost 700,000 SEK) from a returning customer – one of the world’s top five generics companies by revenue. The client uses an ISAB PreciseInhale® aerosol generation system in-house as a central part of its R&D on inhaled pharmaceuticals.

Inhalation Sciences Sweden AB (publ) (”Bolaget”) avhöll den 14 maj 2024 årsstämma i Huddinge. Vid stämman fattades bland annat följande beslut.

Inhalation Sciences AB announces that its Annual Report for 2023 is now available on the company’s website.

Inhalation Sciences AB meddelar att bolagets årsredovisning för 2023 nu finns tillgänglig på bolagets hemsida.

Inhalation Sciences Sweden AB (ISAB) has been invited to provide a public comments presentation at the FDA’s public workshop GDUFA (Generic Drug User Fee Amendments) on May 20[th], 2024.

Aktieägarna i Inhalation Sciences Sweden AB (publ), org.nr 556665-6038, (”Bolaget”) kallas härmed till årsstämma den 14 maj 2024 kl. 13.00 i Bolagets lokaler på Hälsovägen 7 i Huddinge. Rösträttsregistrering startar kl. 12.30.

I ISAB’s bokslutskommuniké för 2023 publicerad den 28e februari 2024, har intäkten från Aprinha projektet redovisats som nettoomsättning. Det gäller intäkter på totalt  642 tkr för 2023.

(Stockholm, 11 March 2024) Positive results from Inhalation Sciences’ first-in-human clinical study of its aerosol generating system PreciseInhale® are now published in a peer-reviewed paper in the European Journal of Pharmaceutical Sciences. The results demonstrate that PreciseInhale® provides greater precision and control than aerosol dosing carried out with a standard commercial inhaler, and can be used for ‘regional targeting’, exposing specific regions of the lungs to a targeted aerosol. The topline results were first communicated on December 20, 2021.

(Stockholm, Sverige, 29 februari 2024) Inhalation Sciences AB meddelar att bolagets delårsrapport för fjärde kvartalet 2023 nu finns tillgänglig på bolagets hemsida.

(Stockholm, Sweden, 28 February 2024) Inhalation Sciences AB announces that its Q4 / Year End Report for 2023 is now available on the company’s website.

Inhalation Sciences AB (ISAB) has signed a new partnership with fellow European inhalation development service provider Actarmo Medical GmbH based in Germany. The new partnership is expected to enlarge the service scope and offerings to the client pipelines of both companies. ISAB and Actarmo have highly complementary services at either end of the respiratory drug development chain, in the fast-growing inhaled therapeutics market.

(Stockholm, Sweden, 29 December,2023) Inhalation Sciences AB (ISAB) has secured a product service contract with a worth of 47,000 Euro on its instruments at the facilities of a large European pharma company. The order reaffirms the client’s strong commitment to its continuing use of ISAB instruments on their robust portfolio of inhaled therapies.

(Stockholm, Sweden, 13 December 2023) Interest and interaction was high on December 11 at ISAB’s latest industry webinar, ‘Inhaled Biologics’. Over 200 scientists registered for the event, the latest in ISAB’s highly popular series, with attendees logging in from Europe, Asia and the US. The webinar was co-hosted by experts in the formulation and drying of biologics, Ziccum AB.

(Stockholm, Sverige, 22 november 2023) Inhalation Sciences AB meddelar att bolagets delårsrapport för tredje kvartalet 2023 nu finns tillgänglig på bolagets hemsida.

(Stockholm, Sweden, 29 August,2023) Inhalation Sciences AB announces that its Q3 Report for 2023 is now available on the company’s website.

Inhalation Sciences AB (ISAB) has received a new order worth 100 kEuro (1.14 MSEK) for an Inhalation Research Services (IRS) project from a major European company with a leading pipeline in inhaled therapies, that is a regular client of both ISAB’s products and services. The project will use ISAB’s XposeALI in vitro exposure module.

(Stockholm, Sweden, 13 November,2023) Inhalation Sciences AB has received a new purchase order worth 276,450 Euro from a returning customer, a large European pharma company with a substantial pipeline of inhaled therapies. The order is for ISAB’s aerosol generating platform PreciseInhale and its unique cell exposure module.

(Stockholm, Sweden, 8 November,2023) Inhalation Sciences AB has signed a new order valued at 54,700 Euro with a customer in Europe developing a generic inhaled drug-device combination therapy. The order is the result of a collaboration with a trusted partner specializing in regulatory tests comparing test and reference inhalers.

Join Inhalation Sciences AB (ISAB) CEO Manoush Masarrat for a 2-minute company pitch and 20-minute analyst Q&A at the livestreamed Redeye Life Science Day, November 23, 2023.

(Stockholm, October 18, 2023) Innovative Swedish MedTech company Inhalation Sciences Sweden AB (ISAB) has strengthened its IP portfolio in the US relating to PreciseInhale® with approval for a new patent.

Inhalation Sciences AB (ISAB) has been awarded a new order from a returning customer for an Inhalation Research Services (IRS) project. The client has once again chosen DissolvIt, ISAB’s in vitro dissolution testing module, known for its precise prediction and comparison of how test generic formulations and originator products perform in the lung. DissolvIt provides a unique advantage for developers of complex generic inhaled therapies. DissolvIt testing is being adopted by a growing number of generic and novel biopharma companies.

Inhalation Sciences AB (ISAB) has signed a collaboration agreement with a leading Indian multinational pharma company with a powerful respiratory portfolio and a major presence in over 80 markets worldwide. The company has chosen DissolvIt[®],[ ]ISAB’s in vitro dissolution and absorption module, for its Inhalation Research project.